The Most Expensive Drug in the World: To Continue or Discontinue, That Is the Question.

Khedraki, Rola; Noor, Zorawar; Rick, James.

Afiliação

Khedraki R; is a resident physician and is chief resident physician, both in internal medicine at the University of California, Irvine. is a staff physician at the Long Beach Healthcare System in California.
Noor Z; is a resident physician and is chief resident physician, both in internal medicine at the University of California, Irvine. is a staff physician at the Long Beach Healthcare System in California.
Rick J; is a resident physician and is chief resident physician, both in internal medicine at the University of California, Irvine. is a staff physician at the Long Beach Healthcare System in California.

Fed Pract ; 33(7): 22-28, 2016 Jul.

Article em En | MEDLINE | ID: mdl-30766188

ABSTRACT

Tailoring treatment based on genetics and medical history may be preferable for patients with atypical hemolytic uremic syndrome who face lifelong therapy on an expensive medication and increased risk of infection.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Fed Pract Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Fed Pract Ano de publicação: 2016 Tipo de documento: Article